During the conference we will be hosting a series of workshops on six key health issues for which Diagnostics are being utilised. These workshops will provide a hands-on, intensive discussion forum on how to improve outcomes via Diagnostics.

Attendees can choose ONE workshop from session 1 and ONE workshop from session 2. You can make note of your preferred workshop on the ticket order form.

Session 1 - 11:50am

Workshop 1 - Sexual Health

Title - Multiplex STI POC Testing: Patient Benefits and Opportunities for Adoption

Current turnaround times for sexually transmitted infections diagnosed by nucleic acid tests are typically four days or longer. This exacerbates the risk of onward transmission, loss to follow up and an increased risk of sequelae, and consequently, symptomatic and high-risk patients are often prescribed antibiotic treatment empirically.

Four key STI pathogens, Chlamydia, Gonorrhoea, Trichomonas and Mycoplasma, often cause similar symptoms but require very different treatments, so inappropriate empirical treatment is a common problem. This workshop will describe a potential solution to diagnose these four key pathogens at the POC, examine the impact on patient health, patient management and also discuss the opportunities and barriers to adoption for this type of test.

Provider - Atlas Genetics

Workshop 2 - Antibiotic Resistance

Title - Reducing prescribing through POC rapid diagnostics

Antimicrobial resistance remains one of the biggest challenges facing the NHS. This workshop will see Professor Jonathan Cooke present the latest data regarding CRP rapid Point of Care testing and how this can support clinical and economic decision making. Finally there will be an opportunity to discuss and get hands on with Abbott's rapid diagnostic- Afinion2 which provides rapid, Lab quality, CRP, HbA1c, Lipids and ACR results

Provider - Abbott (formerly Alere)

Workshop 3 - Diabetes

Title: A Paradigm Shift in the Value Offered by Self Monitoring of Blood Glucose (SMBG)

Diagnostics have a long history in supporting patients with diabetes. Currently, the criteria used to select blood glucose monitoring systems may be based on insignificant minor differences. Little value may be perceived in blood glucose monitoring. Evidence based outcomes to differentiate the systems have been scarce. Now comes a paradigm shift: A novel SMBG platform demonstrates how colours, pattern recognition, and a mobile digital application can help patients understand their blood sugar measurements and engage in remote consultations with their Healthcare provider. This platform is supported by evidence. Let's discuss: What are the opportunities and challenges in adopting this innovation?

Provider - Johnson & Johnson

Facilitator: Nigel Morgan, Medical Lead United Kingdom & Ireland, Johnson & Johnson Diabetes Care Companies

Session 2 - 12:20pm

Workshop 4 - Sepsis

Up to 90% of patients suspected of sepsis are administered IV antibiotics and are confirmed negative for a bloodstream infection at 5-days. How can we improve this situation and support better antimicrobial stewardship as outlined in the O’Neill report 2016? O’Neill calls for a rapid test to rule out bacteria or fungi in blood cultures, so reducing time to conclude that a negative result is real and offering the chance to reduce the length of unnecessary antibiotic treatment by several days. Dr Elizabeth Pilling, Neonatologist at the Jessop Wing, Sheffield Teaching Hospitals, will take us through a study highlighting how we can deal with this challenge today

Provider - Momentum Bioscience

Facilitator - Dr Elizabeth Pilling, Neonatologist at the Jessop Wing, Sheffield Teaching Hospitals

Workshop 5 & 6 Home Care Diagnostics & Cancer - Provided by Croydon University Hospital - The FIT revolution: coming to a GP practice near you

Title - The FIT revolution: coming to a GP practice near you

FIT is a simple test which detects blood in stool. The test can give qualitative (yes/no) or quantitative faecal haemoglobin (F-Hb) readings. While some degree of gastrointestinal bleeding is physiological, F-Hb concentration is related to the severity of disease, and highest in colorectal cancer.

A small pilot study was carried out in Croydon University Hospital to assess the effectiveness of FIT in patients with bowel symptoms referred under the 2 week rule with suspected cancer. The study showed that FIT can reduce the need for the more expensive and time consuming colonoscopy by as much as 80%.

We are conducting a regional and national multicentre study to confirm these results, expected to report at the end of 2018. If proven this could herald a revolution in the way we manage bowel symptoms, saving patients' time in attending hospital appointments and the NHS millions.

Provider - Croydon University Hospital

Facilitator - Mr Muti Abulafi, Consultant Colorectal Surgeon, Croydon University Hospital